Grant: Project Grant - Priority Announcement: Patient-Oriented Research
Ottawa Hospital Research Institute
$100,000.00
The impact of 1-year of adjuvant androgen deprivation following radical prostatectomy on prostate cancer recurrence: An internal pilot randomized trial
EF 2021-22
Résumé
Prostate cancer is the most common cancer in men and radical prostatectomy is the most frequent treatment for this disease. Unfortunately, approximately 40% of patients will develop recurrence after surgery, requiring additional treatments that are often ineffective or have significant risk of side-effects. Prevention of recurrence is an important research priority for prostate cancer patients and their families. Hormonal therapy (androgen deprivation therapy; ADT) is routinely used to treat patients with metastases, but few clinical trials have examined if adjuvant ADT after surgery will prevent cancer recurrence. We aim to address this research oversight and test the hypothesis that for men at high risk of cancer recurrence, 1 year of ADT immediately after surgery will be safe and will significantly improve cancer outcomes. In this proposal we plan to test the feasibility of this trial in Canadian men with prostate cancer.
Programme
Project Grant - Priority Announcement: Patient-Oriented Research
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Other
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
456743
Name
Breau Rodney H
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Randomized Controlled Trials 2
Projecttitle
The impact of 1-year of adjuvant androgen deprivation following radical prostatectomy on prostate cancer recurrence: An internal pilot randomized trial
Programtype2
Operating Grants
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement: Patient-Oriented Research
Keyworddelim
Adjuvant; Androgen Deprivation; High Risk; Prevention Of Recurrence; Prostate Cancer; Radical Prostatectomy; Urology
Abstract
Prostate cancer is the most common cancer in men and radical prostatectomy is the most frequent treatment for this disease. Unfortunately, approximately 40% of patients will develop recurrence after surgery, requiring additional treatments that are often ineffective or have significant risk of side-effects. Prevention of recurrence is an important research priority for prostate cancer patients and their families. Hormonal therapy (androgen deprivation therapy; ADT) is routinely used to treat patients with metastases, but few clinical trials have examined if adjuvant ADT after surgery will prevent cancer recurrence. We aim to address this research oversight and test the hypothesis that for men at high risk of cancer recurrence, 1 year of ADT immediately after surgery will be safe and will significantly improve cancer outcomes. In this proposal we plan to test the feasibility of this trial in Canadian men with prostate cancer.
Competitiondate
202109
Approvedterm2
1 yr 0 mth
Pinamesdelim
Breau, Rodney H; Fergusson, Dean A; Lavallée, Luke T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~
